Evidence map›Paper›PMID 39273023›Full record

ArticleCells2024

Context-Dependent Distinct Roles of SOX9 in Combined Hepatocellular Carcinoma-Cholangiocarcinoma.

Yoojeong Park, Shikai Hu, Minwook Kim, Michael Oertel, Aatur Singhi, Satdarshan P Monga, Silvia Liu, Sungjin Ko

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Co-repression ofbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yoojeong ParkDivision of Experimental Pathology, Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0009-0005-1828-7147
Shikai HuDivision of Experimental Pathology, Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-0817-991X
Minwook KimDivision of Experimental Pathology, Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-0093-4562
Michael OertelDivision of Experimental Pathology, Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Aatur SinghiPittsburgh Liver Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Satdarshan P MongaDivision of Experimental Pathology, Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-8437-3378
Silvia LiuDivision of Experimental Pathology, Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-1840-9520
Sungjin KoDivision of Experimental Pathology, Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-6079-5939

Funding

Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shuchang Silvia Liu · 2019 to 2026
$10.9M
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCCR01CA251155 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LUJAMBIO, AMAIA, MONGA, SATDARSHAN SINGH · 2020 to 2024
$3.1M
Investigating Multifactorial Beta-catenin Activation in Hepatocellular CancersR01CA250227 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Xin Chen, Satdarshan Singh Monga · 2021 to 2026
$3.0M
Blocking hepatocyte senescence as a novel therapeutic strategy for chronic liver diseasesR01DK130949 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OERTEL, MICHAEL, RAEMAN, REBEN · 2021 to 2024
$2.4M
Identifying therapeutic options for intrahepatic cholangiocarcinomaR01CA258449 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KO, SUNGJIN · 2021 to 2025
$1.6M
NCI NIH HHS R01 CA250227NCI NIH HHS R01 CA251155NCI NIH HHS R01 CA258449NIDDK NIH HHS P30 DK120531NIDDK NIH HHS R01 DK130949NIH NCI R01CA258449
6 · The paper itself

Abstract

Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) is a challenging primary liver cancer subtype with limited treatment options and a devastating prognosis. Recent studies have underscored the context-dependent roles of SOX9 in liver cancer formation in a preventive manner. Here, we revealed that liver-specific developmental

Indexed as

Carcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsSOX9 Transcription FactorAnimalsCell ProliferationHumansMiceSox9 protein, mouseSOX9 Transcription Factorbile ductliver cancermixed hepatocellular carcinoma–cholangiocarcinomaNRASplasticitytrans-differentiationYAP1

Identifiers

PMID39273023
PMCPMC11394107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.